Over 22,000 Americans are diagnosed each year with (BMFS) bone marrow failure syndromes. Environmental, chemical, and genetic factors have been linked to the development of lymphomas, leukemias, and myelodysplastic syndromes (MDS). Additionally, some anti-cancer drugs have been shown to themselves induce DNA damage and secondary cancers. In light of increasing societal exposure to toxic environmental agents that may be carcinogenic, including chemicals and pharmaceuticals, or other from processed and/or adulterated foods we face the potential for a rise in the incidence of bone marrow failure and malignancy. In order to better understand leukemia it may be necessary to examine it from the perspective that it is an environmental disease.
ND Pharma & Biotech associated research institutions, are developing and conducting studies in some of this exciting therapy niches in order to understand and develop new targeted therapies. This studies are being conducted from two main perspectives, and by toxicologists who examine the effects of chemicals and the environment on healthy marrow, and hematologists and oncologists who investigate bone marrow abnormalities and malignancies. Thus, there is a clear, unmet need for collaboration between these fields within academia, industry, and government in order to accelerate our investigation and understanding both of basic bone marrow biology and chemically-induced diseases of the marrow.
The company will promote future developments as well as existing therapeutic cellular lineages, to find and commercialize new solutions to some of the described conditions, specifically those affecting infants, child and young adult population, the more affected segments of patients.
Consisten with this line, the company has received Registration Certificate and Code for the new development called AUTOLOGOUS RETRODIFFERENTIATED PLURIPOTENT HEMATOPOIETIC STEM CELLS INFUSION TREATMENT FOR PATIENTS WITH BONE MARROW DEFICIENCY SYNDROME AND OTHER RELATED DISEASES, including the method for retrodifferentiation of such stem cells described within. This developments will open for sure a new pathway for the future treatment and/or cure of dozens of diseases and conditions associated or related to the Bone Marrow Deficiency Failure Syndrom.
Comments are closed.
Welcome to ND NEWS.